Alterations of the cellular levels of PTEN, miRNAs, and PTENP1 presents a new frontier in cancer therapeutics with the potential to reverse the cancer phenotype through the positive manipulation of the PTEN–miRNA–PTENP1 axis in favour of pre-cancer levels and induce a pre-cancerous cellular phenotype. The gene discussed is PTEN; the disease is cancer.